|Stock Name : Cipla Limited/Tips Open||Buy : 781.45||Posted Date : Sep 30, 2020|
|Stopless/Horizon : 600||Target : 1000||Results Achieved (Yes/No) :|
Overview: Cipla limited is one of the leading pharmaceutical companies in India. The company wasestablished in 1935, it is a Large Cap company with a market capital of Rs 61929.68 Crore.
About the company: The Company was incorporated in 1935 as Chemical, Industrial & Pharmaceutical Laboratories Limited by Dr. Khwaja Abdul Hamied in Mumbai. On August 17, 1935, Cipla was registered as a public limited company with an authorized capital of Rs 6 lakh.
Today,Cipla has extended their presence to 80+ countries with product portfolio over 1,500 products across wide range of therapeutic categoriesin 50+ dosage forms. The turnover of Cipla is 2.3 BillionUSD.With 25,000+ employees, Cipla has 46 state-of-the-art facilities including API and Formulations.
Cipla offer prescription drugs, bulk drugs, animal products, pesticides, a wide range of food and beverages, baked foods, oral hygiene products, detergents, room fresheners and personal care products.
The company offers drugs used for the treatment of cancer, Alzheimer`s, arthritis, Parkinson’s, cardiovascular diseases,drugs that prevents transmission of AIDS from mother to child, provide consulting services on preparation of products and materials, conducts plant evaluation and supplies plant equipment.
Cipla Limited’s largest market is India, followed by Africa and North America (Cipla is ranked amongst the top 10 most dispensed generic companies in North America). The company’s total revenue reached Rs 17,132 crore (USD 2.43 billion) in FY20.
Management: Dr. Y. K. Hamied is the Chairman and Mr. Umang Vohra is the Managing Director & Global Chief Executive Officer of
Shareholding Pattern (As on June 2020):
• Promoters and Promoter Group – 36.65
• Foreign Institutional Investors – 18.63
• Indian Institutional Investors – 21.05
• GDR – 0.09
• Others – 23.58
Dividend: Cipla declared an equity dividend of 200.00% amounting to Rs 4 per sharefor the year ending March 2020.
Sales Report:For the quarter ended on 30th June 2020, Cipla posted a consolidated sale of Rs 4276.89 Crore, which was down by -.57 % from previous quarter’ssales of Rs 4301.60 Crore, but up by 9.82 % from corresponding year’s same quarter sales of Rs 3894.46.
If you find any mistake please contact the firstname.lastname@example.org. This article is general in nature. It does not constitute a recommendation to buy and sell any stock, and does not take account of your objectives, or your financial situation. Largecapindia has no position in the stocks mentioned.
Largecapindia aim to bring you long term focused research analysis driven by fundamental thanks you.
For More Info : https://www.largecapindia.com